Article Sidebar

pdf
Date Published: 02/12/2025
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v556i1.16320
Issue
Vol. 556 No. 1 (2025)
Section
Các bài báo
How to Cite
Lê, T. P., & Huỳnh, T. X. T. (2025). ANTIFUNGAL RESISTANCE OF CANDIDA SPP. IN PATIENTS WITH VULVOVAGINAL CANDIDIASIS AT HO CHI MINH CITY HOSPITAL OF DERMATOLOGY AND VENEREOLOGY. Vietnam Medical Journal, 556(1). https://doi.org/10.51298/vmj.v556i1.16320

ANTIFUNGAL RESISTANCE OF CANDIDA SPP. IN PATIENTS WITH VULVOVAGINAL CANDIDIASIS AT HO CHI MINH CITY HOSPITAL OF DERMATOLOGY AND VENEREOLOGY

Thảo Phúc Lê, Thị Xuân Tâm Huỳnh

Main Article Content

Abstract

Objective: To determine the antifungal resistance rate of Candida spp. isolated from patients with vulvovaginal candidiasis at Ho Chi Minh City Hospital of Dermatology and Venereology. Subject and Methods: A cross-sectional descriptive study. Vaginal discharge samples were collected from 70 women diagnosed with vulvovaginal candidiasis at Ho Chi Minh City Hospital of Dermatology and Venereology from March 2025 to July 2025. The specimens were cultured and identified on Sabouraud dextrose agar and CHROMagar™ Candida media. Antifungal susceptibility testing against azole agents was performed using the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: A total of 73 Candida isolates were obtained: C. albicans 83.6%, C. glabrata 9.6%, C. tropicalis 4.1%, and C. parapsilosis 2.7%. The median MICs for C. albicans were 0.0625 µg/mL for itraconazole and 0.5 µg/mL for fluconazole, with resistance rates of 50.8% and 16.4%, respectively. Candida non-albicans species exhibited high resistance to both drugs (71.4–100%). Conclusion: C. albicans remains the predominant causative agent of vulvovaginal candidiasis; however, an increasing trend of highly resistant Candida non-albicans species has been observed. Species identification and antifungal susceptibility testing prior to treatment are essential to guide appropriate therapy and help mitigate antifungal resistance in the community.

Article Details

Keywords

Vulvovaginal candidiasis, Candida spp., drug resistance, itraconazole, fluconazole

References

1. Workowski KA. Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports. 2021;70.
2. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. Published online 2015.
3. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis. Journal of Fungi. 2018; 4(4):121.
4. Anh DN, Hung DN, Tien TV, et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam. BMC infectious diseases. 2021;21(1):523.
5. Châu NTM, Anh TNP. Xác định loài vi nấm và đánh giá sự đề kháng với một số thuốc kháng nấm của các loài nấm Candida sp. gây viêm âm đạo phân lập được ở Bệnh viện Trường Đại học Y Dược Huế. Tạp chí Phụ sản. 2016;13(4):44-47.
6. Dovo EE, Sorgho A, Ouedraogo E, et al. Vulvovaginal Candidiasis: Profile of Antifungal Susceptibility Test of Candida Strains to Antifungal Drugs from 2018 to 2022, Ouagadougou, Burkina Faso. Advances in Microbiology. 2025;15(1):58-69.
7. Hösükoğlu FG, Ekşi F, Erinmez M, Uğur MG. An epidemiologic analysis of vulvovaginal candidiasis and antifungal susceptibilities. Infectious Microbes & Diseases. 2022;4(3):131-136.
8. Liu X, Fan S, Peng Y, Zhang H. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. Journal de mycologie medicale. 2014;24(2):106-111.